Other analysts have also issued research reports about the company. Craig Hallum raised PROS from a “hold” rating to a “buy” rating and upped their price objective for the stock from $36.00 to $60.00 in a research report on Friday, April 26th. Benchmark reaffirmed a “hold” rating on shares of Western Digital in a research report on Friday, April 26th. TheStreet lowered Trinity Industries from a “b” rating to a “c” rating in a research report on Thursday, April 25th. BidaskClub lowered Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Finally, Zacks Investment Research raised Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Monday, April 29th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Omnicell presently has an average rating of “Buy” and an average target price of $79.89.
Omnicell stock opened at $68.61 on Friday. Omnicell has a twelve month low of $52.20 and a twelve month high of $92.59. The stock’s fifty day moving average is $83.41. The company has a quick ratio of 1.47, a current ratio of 1.96 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 44.84, a P/E/G ratio of 2.44 and a beta of 1.13.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The business had revenue of $202.50 million for the quarter, compared to analyst estimates of $199.72 million. During the same quarter in the prior year, the company earned $0.29 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Omnicell will post 2.06 EPS for the current year.
In related news, Chairman Randall A. Lipps sold 65,161 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $63.77, for a total value of $4,155,316.97. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nhat H. Ngo sold 4,948 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $87.08, for a total value of $430,871.84. Following the completion of the transaction, the executive vice president now directly owns 30,321 shares in the company, valued at approximately $2,640,352.68. The disclosure for this sale can be found here. Insiders sold 146,028 shares of company stock worth $10,741,639 in the last three months. 2.77% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. NN Investment Partners Holdings N.V. acquired a new stake in shares of Omnicell during the second quarter worth about $1,684,000. Scout Investments Inc. boosted its stake in shares of Omnicell by 58.9% during the second quarter. Scout Investments Inc. now owns 196,336 shares of the company’s stock worth $16,891,000 after buying an additional 72,762 shares during the period. Copper Rock Capital Partners LLC boosted its stake in shares of Omnicell by 10.9% during the second quarter. Copper Rock Capital Partners LLC now owns 230,988 shares of the company’s stock worth $19,872,000 after buying an additional 22,738 shares during the period. Northeast Financial Consultants Inc acquired a new stake in shares of Omnicell during the first quarter worth about $323,000. Finally, Westwood Holdings Group Inc. boosted its stake in shares of Omnicell by 5.1% during the first quarter. Westwood Holdings Group Inc. now owns 388,238 shares of the company’s stock worth $31,385,000 after buying an additional 18,897 shares during the period. 97.30% of the stock is currently owned by hedge funds and other institutional investors.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.